share_log

EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Adage Capital Management, L.P.(10.35%),Robert Atchinson(10.35%), etc.

EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Adage Capital Management, L.P.(10.35%),Robert Atchinson(10.35%), etc.

EyePoint Pharmaceuticals | SC 13G：超过5%持股股东披露文件-Adage Capital Management, L.P.(10.35%),Robert Atchinson(10.35%)等
美股sec公告 ·  05/01 08:57
牛牛AI助手已提取核心信息
EyePoint Pharmaceuticals, Inc. has been the subject of a Schedule 13G filing with the Securities and Exchange Commission, indicating a significant investment by Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross. The filing, dated April 30, 2024, reports that Adage Capital Management, L.P., along with Atchinson and Gross, collectively hold 5,156,299 shares of EyePoint Pharmaceuticals' common stock, which represents 10.35% of the company's class of securities. This level of ownership classifies them as major shareholders, as they own more than 5% of the company's common stock. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, which is typically used by passive investors. The address for the principal business office of the reporting persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. The filing emphasizes that the acquisition of the shares is in the ordinary course of business and not with the purpose of changing or influencing the control of EyePoint Pharmaceuticals.
EyePoint Pharmaceuticals, Inc. has been the subject of a Schedule 13G filing with the Securities and Exchange Commission, indicating a significant investment by Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross. The filing, dated April 30, 2024, reports that Adage Capital Management, L.P., along with Atchinson and Gross, collectively hold 5,156,299 shares of EyePoint Pharmaceuticals' common stock, which represents 10.35% of the company's class of securities. This level of ownership classifies them as major shareholders, as they own more than 5% of the company's common stock. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, which is typically used by passive investors. The address for the principal business office of the reporting persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. The filing emphasizes that the acquisition of the shares is in the ordinary course of business and not with the purpose of changing or influencing the control of EyePoint Pharmaceuticals.
EyePoint Pharmicals, Inc.一直是向美国证券交易委员会提交的附表13G文件的主体，这表明Adage Capital Management, L.P. 以及个人罗伯特·阿钦森和菲利普·格罗斯进行了大量投资。这份日期为2024年4月30日的文件显示，Adage Capital Management, L.P. 以及阿钦森和格罗斯共持有EyePoint Pharmaceuticals普通股的5,156,299股，占该公司证券类别的10.35％。这种所有权水平将他们归类为主要股东，因为他们拥有公司5％以上的普通股。这些股份以共同的投票权和处置权持有。该文件是根据1934年《证券交易法》第13d-1（b）条提交的，该法通常由被动投资者使用。申报人主要业务办公室的地址是马萨诸塞州波士顿克拉伦登街200号52楼02116。该文件强调，收购这些股份属于正常业务流程，其目的不是改变或影响EyePoint Pharmicals的控制权。
EyePoint Pharmicals, Inc.一直是向美国证券交易委员会提交的附表13G文件的主体，这表明Adage Capital Management, L.P. 以及个人罗伯特·阿钦森和菲利普·格罗斯进行了大量投资。这份日期为2024年4月30日的文件显示，Adage Capital Management, L.P. 以及阿钦森和格罗斯共持有EyePoint Pharmaceuticals普通股的5,156,299股，占该公司证券类别的10.35％。这种所有权水平将他们归类为主要股东，因为他们拥有公司5％以上的普通股。这些股份以共同的投票权和处置权持有。该文件是根据1934年《证券交易法》第13d-1（b）条提交的，该法通常由被动投资者使用。申报人主要业务办公室的地址是马萨诸塞州波士顿克拉伦登街200号52楼02116。该文件强调，收购这些股份属于正常业务流程，其目的不是改变或影响EyePoint Pharmicals的控制权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。